Calls for IVF laws to be changed to take advantage of gene editing technique
By Steve Connor,
The Independent
| 09. 02. 2015
Untitled Document
Britain may need to change its IVF laws to allow the genetic modification of human embryos so that scientists can use a gene-editing technique that could eliminate certain inherited diseases, leading biomedical organisations warn.
At present it is illegal to alter the genes of reproductive “germ cells” such as eggs, sperm and embryos, but the clinical benefits of modifying the human germ-line could one day outweigh the ethical objections, says a statement by two government research councils and a coalition of medical research charities.
While the US has imposed a moratorium on the use of genome editing of human embryos, the joint statement implies that the day might soon come in the UK when it is ethically justified to implant the first genetically modified embryo in a womb. The research organisations, which include the Medical Research Council and the Wellcome Trust, Britain’s biggest medical charity, said there was no reason why the gene-editing technique known as Crispr-Cas9 should not be used immediately on early IVF embryos for research purposes provided they are not implanted into the womb –...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...